Biocon Biologics gets eight observations from USFDA for Malaysia insulin facility

The US drug regulator issued 6 observations for drug substance, drug product units and quality Control laboratories and 2 observations for the delivery devices unit of Biocon Sdn Bhd, Malaysia, a subsidiary of Biocon Biologics.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news